Miyake Makito, Nishimura Nobutaka, Oda Yuki, Miyamoto Tatsuki, Tomizawa Mitsuru, Shimizu Takuto, Hori Shunta, Morizawa Yosuke, Gotoh Daisuke, Nakai Yasushi, Torimoto Kazumasa, Fujii Tomomi, Tanaka Nobumichi, Fujimoto Kiyohide
Department of Urology, Nara Medical University, Kashihara, Nara, Japan.
Department of Diagnostic Pathology, Nara Medical University, Kashihara, Nara, Japan.
J Chemother. 2025 Apr;37(2):146-158. doi: 10.1080/1120009X.2024.2340885. Epub 2024 Apr 17.
A time-course questionnaire survey using the chemotherapy-induced taste alteration scale (CiTAS) was conducted in patients with advanced urothelial carcinoma (UC) treated with systemic chemotherapy and/or immunotherapy. A total of 37 patients receiving systemic therapy with enfortumab vedotin (EV), platinum-based chemotherapy and immune checkpoint inhibitors were included in this study. No significant changes were observed in any of the CiTAS subscales during platinum-based chemotherapy and immune checkpoint inhibitor treatment, while EV therapy induced significant dysgeusia. Among 10 patients treated with EV, dysgeusia was associated with a substantial negative effect on the health-related quality-of-life domains, particularly global health status/QOL (mean ± standard deviation: 52 ± 19 in dysgeusia group vs 89 ± 13 in non-dysgeusia group) and mental component summary (47 ± 5.1 vs 53 ± 2.0). The fatigue symptom score was higher in the dysgeusia group at the post-third cycle of EV (47 ± 16 vs 15 ± 17). Severe dysgeusia can be induced by EV therapy, which is usually not observed in other systemic therapies for advanced UC.
对接受全身化疗和/或免疫治疗的晚期尿路上皮癌（UC）患者进行了一项使用化疗引起的味觉改变量表（CiTAS）的时间进程问卷调查。本研究共纳入37例接受安维汀（EV）、铂类化疗和免疫检查点抑制剂全身治疗的患者。在铂类化疗和免疫检查点抑制剂治疗期间，CiTAS的任何子量表均未观察到显著变化，而EV治疗可引起显著的味觉障碍。在10例接受EV治疗的患者中，味觉障碍对健康相关生活质量领域有重大负面影响，尤其是总体健康状况/生活质量（平均±标准差：味觉障碍组为52±19，无味觉障碍组为89±13）和心理成分总结（47±5.1对53±2.0）。在EV治疗的第三个周期后，味觉障碍组的疲劳症状评分更高（47±16对15±17）。EV治疗可引起严重的味觉障碍，这在晚期UC的其他全身治疗中通常未观察到。
